EUCTR2011-005174-27-BE进行中（未招募）1 期
Phase II study of High-Dose Rituximab in High Risk Chronic Lymphocytic Leukemia in Suboptimal Response after Induction Immunochemotherapy - HYDRIC
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- B-cell CLL defined by standard NCI criteria in first line or in relapse
- •- > 18 year-old
- •- Presence of MRD (MRD positivity) by FCM criteria (standardized 7/8-color FCM) in these two clinical situations :
- •1.Patients in CR (defined by standard criteria including BM examination) after rituximab-containing ICT, who show persisting MRD either in blood at least 6 months after the last dose of rituximab-containing chemoimmunotherapy or in BM at least 3 months after the last dose of rituximab-containing ICT
- •2.Patients in continuous CR but who show MRD relapse in PB or BM without clinical progression (as defined by NCI) at any time after ICT
- •- ICT should have comprised:
- •1. Rituximab combined with fludarabine, with or without an alkylating drug, with or without an anthracyclin (ex: FR, FCR, FCRM…)
- •2. At least 4 cycles
- •- Patients should have recovered from the toxicities of ICT
- •- POOR PROGNOSTIC FEATURES (before induction) defined by at least one of the following markers: stage C Binet before induction ICT, unmutated IgVH genes, 17p deletion, 11q deletion, Zap-70 positivity, high CD38, mutated IgVH genes if VH3-21 usage
- •- In addition, in patients with 11q deletion, absence of profound lymph nodes should have been excluded by CT scan
- •- CIRS < 6
- •- Absence of geriatric risk profile as determined by using the G8 geriatric screening tool if patient aged > 70 years
- •- Performance status (ECOG) < 2
- •- Neutrophils > 1000/microL, platelets > 100,000/microL
- •- Creatinine clearance > 50 ml/min (clearance can be reevaluated after adequate hydration of the patient)
- •- Patient’s written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •- Less than CR response after ICT
- •- Ongoing active infections (bacterial, viral or fungal)
- •- Other uncontrolled malignant disease
- •- Known infection with HIV
- •- Subjects with any serological evidence of current or past hepatitis B or hepatitis C exposure are excluded unless the serological findings are clearly due to vaccination
- •- Concomitant treatment with steroids, or any immunosuppressive drug
- •- Ongoing auto-immune phenomena, clinically significant
- •- Transformation into an aggressive B-cell malignancy (eg. diffuse large B-cell lymphoma, Hodgkin lymphoma)
- •- Pregnancy, breast feeding, females of childbearing potential or male patients who are unwilling to use adequate contraception
- •- Intolerance to rituximab
- •- Concomitant severe disease (uncompensated cardiac insufficiency, severe respiratory insufficiency…)
- •- Severe hypogammaglobulinemia with recurrent infections, unless the patient is receiving substitutive IV immunoglobulins
- •- Transaminases > 3x ULN
- •- Conjugated bilirubin > 2x ULN
- •- Prior autologous stem cell transplantation less than 12 months
- •- Prior allogeneic stem cell transplantation
- •- CNS involvement
- •- Any coexisting medical or psychological condition that would preclude participation to the required study procedures
- •- Prior history of malignancies, other than CLL, unless subject has been free of the disease for >= 5 years. Exceptions include the following: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histologic finding prostate cancer (TNM stage of T1a or T1b).
研究者
相似试验
终止
2 期
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction ImmunochemotherapyChronic Lymphocytic LeukemiaNCT01625741Cliniques universitaires Saint-Luc- Université Catholique de Louvain6
进行中（未招募）
1 期
Multicenter study of phase II with Rituximab, cyclophosphamide, doxorubicin liposomal (Myocet), vincristine, Prednisone, (R-COMP) in diffuse Non-Hodgkin`s lymphoma, large B cells of the cardiopathic patient - HEART01Diffuse Non-Hodgkin`s lymphoma, large B cells of the cardiopathic patientMedDRA version: 9.1Level: PTClassification code 10012818EUCTR2009-012143-42-ITIIL INTERGRUPPO ITALIANO LINFOMI ONLUS50
已完成
不适用
Phase II study of Rituximab in Patients with Systemic Lupus ErythematosusSystemic lupus erythematosusJPRN-UMIN000000762Zenyaku Kogyo Co., Ltd.70
进行中（未招募）
不适用
Phase II Trial of Rituximab Plus 2CdA in Patients with Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)ymphoma of the Mucosa-Associated Lymphoid Tissue (MALT)MedDRA version: 9.1Level: LLTClassification code 10060707Term: MALT lymphomaEUCTR2008-000767-41-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
已完成
2 期
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphomaJPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40